Secretin hormone research variant: [Tyr10] Secretin-27
A lab-made version of secretin, a gut hormone, studied in mice to see how it crosses the brain's protective barrier; used only as a lab research tool.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Snapshot
Class: Synthetic secretin analog
Evidence tier: Animal-only evidence
Status: No approved therapeutic status identified
Best-supported effect: Studied for differential transport across the blood–brain and blood–cerebrospinal fluid barriers in mouse models
Main caveat: Single mouse transport study; no efficacy, no human data, no functional therapeutic endpoint established
What this is
[Tyr10] Secretin-27 is a 27-amino-acid synthetic analog of secretin, a gastrointestinal hormone belonging to the VIP/glucagon/PACAP peptide family. The analog carries a threonine-to-tyrosine substitution at position 10 of the native secretin sequence. It has been studied as a tool compound to investigate peptide transport across the blood–brain barrier (BBB) and blood–cerebrospinal fluid barrier (BCSFB) in mice. No therapeutic indication or efficacy claim is supported by the available literature for this card.
Evidence map
| Evidence layer | Grade | What it supports |
|---|---|---|
| Human | None | No human evidence identified |
| Animal | Weak | Single mouse in vivo study of BBB and BCSFB transport pharmacokinetics; no efficacy endpoint |
| In vitro | None | No cell or assay evidence identified |
| Computational | None | No computational or structural prediction data identified |
| Mechanism | Plausible | Secretin-family receptor biology is established for the parent molecule; analog-specific mechanism not established in available literature |
The sole animal-model evidence is a mouse pharmacokinetic/transport study (Banks et al., 2002) examining differential transport of a secretin analog across the BBB and BCSFB. This study does not provide efficacy, receptor binding, or therapeutic endpoint data.
Claim check
| Claim | Verdict | Evidence layer | Confidence |
|---|---|---|---|
| Undergoes differential transport across the blood–brain and blood–cerebrospinal fluid barriers | Supported (animal) | Animal — single mouse transport study | Low — single study, no human replication |
| Therapeutic efficacy for any indication | Not established | None | High — no efficacy data in source |
| Equivalence to native secretin-27 in receptor activity or biological effect | Not established | None | High — no receptor binding or functional assay data in source |
Experimental exposure
This section reports exposure used in animal experiments. It does not establish human dosing.
| Context | System | Experimental exposure | Duration | Endpoint | Limitation |
|---|---|---|---|---|---|
| Animal transport study | Mouse (in vivo) | Exact dose and administration route not individually extracted | Single timepoint study | Differential transport across BBB and BCSFB | Single study; no efficacy endpoint; no human translation established |
Preclinical safety signals
No toxicology or safety data are identifieds available literature. The sole animal study examined transport pharmacokinetics; no adverse event or toxicology endpoint is reported in available literature.
Regulatory status
No approved therapeutic status identified in the available literature. This card describes a synthetic research analog, not an approved medicine.
| Region / body | Status |
|---|---|
| US (FDA) | No approved status identified in source |
| EU (EMA) | No approved status identified in source |
| WADA | Not checked in available literature |
Mechanism
Secretin, the parent molecule, acts through the secretin receptor (SCTR), a class B G protein-coupled receptor expressed in the pancreas, gastrointestinal tract, kidney, and brain. Receptor activation stimulates adenylate cyclase, raising intracellular cAMP and driving downstream effects including bicarbonate secretion from pancreatic ductal cells. The [Tyr10] analog substitutes tyrosine for threonine at position 10 of the native sequence. The functional consequences of this substitution on receptor binding affinity, selectivity, or downstream signaling are not established in the available literature. The Banks et al. (2002) study used this analog to probe CNS transport, not to characterize receptor activity or therapeutic mechanism.
Chemistry
| Field | Value |
|---|---|
| Full name | [Tyr10] Secretin-27 |
| Amino-acid sequence | H-His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Tyr-Ser-Arg-Leu-Arg-Asp-Ser-Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Gly-Leu-Val-OH |
| One-letter notation | HSDGTFTSEYSRLRDSARLQRLLQGLV |
| Length | 27 amino acids |
| Topology | Linear |
| Key modification | Thr→Tyr substitution at position 10 (native secretin has Thr at position 10) |
| Molecular weight | Not provided in source |
| Formula | Not provided in source |
| CAS | Not provided in source |
| Sequence confidence | Needs review — sequence provided by single CU source; no cross-source verification |
Open questions
- Receptor binding and selectivity: No binding affinity data (Ki, IC50, EC50) for the secretin receptor or related receptors are provided in available literature. The functional impact of the Thr10→Tyr10 substitution on receptor activity is unknown.
- Reason for Tyr10 substitution: the available literature does not explain the design rationale for position-10 tyrosination. Whether this modification was intended to introduce a radiolabel handle, alter receptor affinity, or probe structure–activity relationships is not established in this card.
- In vitro and functional characterization: No cell-based assay, receptor binding assay, or functional endpoint data are attached.
- Human translation: No human pharmacokinetic or efficacy data have been identified in available literature.
- Long-term safety: No toxicology or chronic exposure data are attached.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.9199624061584473 | boltz-2 |
| ranking score | 0.6989994049072266 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | colabfold_local |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-22 |
▸citationbibtex
@peptide{pep10593,
sequence = {HSDGTFTSEYSRLRDSARLQRLLQGLV},
target = {sctr},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}